This is a working overview of 非天然氨基酸, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-10. Anything still debated is marked as such rather than presented as settled.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
杂质谱一般包含缺失序列片段、差向异构体、氧化产物以及残留溶剂或反离子，其中组氨酸与芳香残基的氧化常被重点关注。反相色谱中这类杂质往往紧邻主峰洗脱，因此方法需要足够的分离度并经过系统适用性验证。纯度百分比的解读依赖于检测波长与梯度条件，不同实验室公布的数字不宜直接横向比较。参考标准品有助于跨批次对照，但其自身赋值同样需要可追溯来源。
冻干状态下的肽通常比溶液状态更稳定，常规做法是维持 -20 °C 或更低温度、保持干燥并避开强光。复溶后的降解主要来自水解、氧化与脱酰胺，速率受 pH、缓冲液种类、离子强度与温度共同影响，碱性条件一般会加快这些反应。反复冻融会造成聚集与容器吸附损失，分装保存能降低该风险。容器材质与金属离子也可能参与氧化过程，需与操作条件一并考虑。
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with C-terminal amide |
| Average mass | Approximately 711.9 Da | Value derived from the formula |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and aqueous acetonitrile | Dissolution aided by acidic diluents |
| Common synonyms | Ipamorelin; NNC 26-0161 | Code name used in early reports |
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Ipamorelin 是一种合成五肽，序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2，分子式 C38H49N9O5，游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素（GHS）家族，作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道，设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。
在 GHS 家族中，早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放，并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性，对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同，而完整的分子解释仍有待补充。需要区分的是，选择性是研究观察中的相对程度，并非绝对界限。
1950: Fujirebio (formerly Fujizoki Pharmaceutical, Co., Inc.) is founded in Tokyo, Japan. 1966: Launch of HA Ag (TPHA), the world's first hemagglutination test for syphilis. 1981: Established Fujirebio Taiwan Inc. 1987: Established Fujirebio America, Inc. (merged to Fujirebio Diagnostics, Inc.) in the United States. 1998: Acquisition of Centocor Diagnostics of Pennsylvania, Inc. (USA, currently Fujirebio Diagnostics, Inc.), pioneer in oncology testing and developer of CA125II, CA19-9 and CA15-3. 2006: Acquisition of CanAg Diagnostics AB (Sweden, currently Fujirebio Diagnostics AB), leader in oncology biomarker development. 2007: Launch of CL4800 in Japan to support blood screening for the Japanese Red Cross Society (~2019). 2008: Acquisition of Advanced Life Science Institute, Inc. 2008: Acquisition of American Biological Technologies, Inc. (merged to Fujirebio Diagnostics, Inc.). 2010: Acquisition of Innogenetics N.V. (Belgium, currently Fujirebio Europe N.V.), world leader in specialty molecular and immunoassay testing. 2017: Established Fujirebio Holdings, Inc., as parent company of Fujirebio Inc., Fujirebio Diagnostics, Inc., Fujirebio Europe N.V. and other Fujirebio group companies. 2019: Established Fujirebio Diagnostics Japan, Inc., focusing on OEM business in Japan. 2020: Established Fujirebio China Co., Ltd. 2022: Acquisition of ADx NeuroSciences. 2022: Acquisition of Fluxus, Inc. 2025: Acquisition of Plasma Services Group, Inc.
== Pharmacology == Diphenoxylate is rapidly metabolized to difenoxin; it is eliminated mostly in feces but also in urine. Like other opioids, diphenoxylate acts by slowing intestinal contractions, allowing the body to consolidate intestinal contents and prolong transit time, thus allowing the intestines to draw moisture out of them at a normal or higher rate and therefore stop the formation of loose and liquid stools; the atropine is an anticholinergic and is present to prevent drug abuse and overdose. Diphenoxylate has moderate binding affinity for the μ-opioid receptor in humans at 12.37 nM (Morphine 1.168).
This concept is of clinical interest as it is sometimes necessary to reach a certain concentration of a drug that is known to be optimal in order for it to have the required effects on the organism (as occurs if a patient is to be scanned).
Sources: en.wikipedia.org
== Associated disorders == The most common associated disorder is pre-eclampsia, affecting approximately 7% of all births. It is characterized by a failure of the cytotrophoblast to invade the uterus and its vasculature, specifically the spiral arteries that the endovascular cytotrophoblast should invade. The result of this is decreased blood flow to the fetus which may cause intrauterine growth restriction. Clinical symptoms of pre-eclampsia in the mother are most commonly high blood pressure, proteinuria and edema. Conversely, if there is too much invasion of uterine tissue by the trophoblast then a hydatidiform mole or choriocarcinoma may arise.
=== Soundtrack === Most of the soundtrack is non-lyrical ambient music composed by Kelly Bailey and Mike Morasky, somewhat dark and mysterious to match the mood of the environments. The closing credits song, "Still Alive", was written by Jonathan Coulton and sung by Ellen McLain (a classically trained operatic soprano) as the GLaDOS character. A brief instrumental version of "Still Alive" is played in an uptempo Latin style over radios in-game. Wolpaw notes that Coulton was invited to Valve a year before the release of Portal, though it was not yet clear where Coulton would contribute. "Once Kim [Swift] and I met with him, it quickly became apparent that he had the perfect sensibility to write a song for GLaDOS." The use of the song over the closing credits was based on a similar concept from the game God Hand, one of Wolpaw's favorite titles. The song was released as a free downloadable song for the music video game Rock Band on April 1, 2008. The soundtrack for Portal was released as a part of The Orange Box Original Soundtrack. The soundtrack was released in a four-disc retail bundle, Portal 2: Songs To Test By (Collector's Edition), on October 30, 2012, featuring music from both games. The soundtrack was released via Steam Music on September 24, 2014.
==== Role in cardiac hypertrophy and fibrosis ==== Intracrine Ang II has been implicated in the development of cardiac hypertrophy, a process characterized by the enlargement of cardiac myocytes in response to increased workload or stress. Experimental models have shown that overexpression of non-secreted Ang II in cardiac cells leads to rapid hypertrophy independent of extracellular Ang II signaling. This suggests that intracellular Ang II plays a direct role in cardiomyocyte growth and structural remodeling. Similarly, intracrine Ang II contributes to myocardial fibrosis by upregulating profibrotic cytokines and growth factors, such as transforming growth factor-beta (TGF-β) and platelet-derived growth factor (PDGF). This promotes the excessive deposition of extracellular matrix proteins, leading to stiffening of the cardiac tissue and impaired cardiac function.
Sources: en.wikipedia.org
Although the label cited worry about blowback from United States President Donald Trump due to the lyrics, Pusha T publicly claimed it was over his and Lamar's public feuds with rapper Drake, who filed a lawsuit against Universal in 2025 for its publication of Lamar's diss "Not Like Us". Refusing to censor the verse, Clipse paid a seven-figure sum to be dropped from the deal, signing a distribution deal with Roc Nation instead but giving Def Jam a percentage of the profits from the album. The album's lyrical content and promotional press received media attention for Pusha T's outspoken criticism of his rivals Drake and Jim Jones, as well as former creative partners Kanye West and Travis Scott. Let God Sort Em Out received critical acclaim upon release, with critics praising the duo's raw, introspective lyricism and longstanding chemistry. It was preceded by one single, "Ace Trumpets", released on May 30, 2025. Although no other songs were released as standalone singles, "Chains & Whips" and "So Far Ahead" were serviced to Apple Music the evening before its release; the former would also receive a music video along with "So Be It". Clipse embarked on the Let God Sort Em Out Tour with EarthGang from August to November 2025 in additional promotion of the album.
A launch failure on 21 April 1964 in which the U.S. Transit-5BN-3 navigation satellite failed to achieve orbit and burned up on re-entry north of Madagascar. The 17,000 Ci (630 TBq) plutonium metal fuel in its SNAP-9a RTG was ejected into the atmosphere over the Southern Hemisphere where it burned up, and traces of plutonium-238 were detected in the area a few months later. This incident resulted in the NASA Safety Committee requiring intact reentry in future RTG launches, which in turn impacted the design of RTGs in the pipeline. The Nimbus B-1 weather satellite, whose launch vehicle was deliberately destroyed shortly after launch on 21 May 1968 because of erratic trajectory. Launched from the Vandenberg Air Force Base, its SNAP-19 RTG containing relatively inert plutonium dioxide was recovered intact from the seabed in the Santa Barbara Channel five months later and no environmental contamination was detected. In 1969 the launch of the first Lunokhod lunar rover mission failed, spreading polonium-210 over a large area of Russia. The failure of the Apollo 13 mission in April 1970 meant that the Lunar Module reentered the atmosphere carrying an RTG and burned up over Fiji. It carried a SNAP-27 RTG containing 44,500 Ci (1,650 TBq) of plutonium dioxide in a graphite cask on the lander leg which survived reentry into the Earth's atmosphere intact, as it was designed to do, the trajectory being arranged so that it would plunge into 6–9 kilometers of water in the Tonga trench in the Pacific Ocean.
Ethylene oxide is one of the most important raw materials used in large-scale chemical production. Most ethylene oxide is used for synthesis of ethylene glycols, including diethylene glycol and triethylene glycol, that accounts for up to 75% of global consumption. Other important products include ethylene glycol ethers, ethanolamines, and ethoxylates. Among glycols, ethylene glycol is used as antifreeze, in the production of polyester and polyethylene terephthalate (PET – raw material for plastic bottles), liquid coolants, and solvents.
Sources: en.wikipedia.org
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.
It has not received marketing approval as a medicine in the United States or the European Union. Supplied material is generally described and handled as a research chemical. Regulatory treatment varies by jurisdiction, and some countries restrict growth hormone secretagogues under sports or medicines legislation.
Earlier secretagogues were associated with broader hormonal responses, including measurable changes in cortisol and prolactin. Reports on this peptide describe a narrower profile in which growth hormone release is the most prominent effect. The observation is influential because it shapes how the compound is compared with other members of the same receptor family.
肽键在 214 nm 附近有较强吸收，适合检测缺少芳香侧链的短肽。该波长的基线受流动相组成与梯度影响较大。因此流动相与梯度条件需要固定并完整记录。